keyword
MENU ▼
Read by QxMD icon Read
search

Ics copd

keyword
https://www.readbyqxmd.com/read/29785104/respiratory-medication-used-in-copd-patients-from-seven-latin-american-countries-the-lassyc-study
#1
Alejandro Casas, Maria Montes de Oca, Ana Mb Menezes, Fernando C Wehrmeister, Maria Victorina Lopez Varela, Laura Mendoza, Larissa Ramírez, Marc Miravitlles
Background: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region. Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29783858/effectiveness-and-safety-comparison-for-systemic-corticosteroid-therapy-with-and-without-inhaled-corticosteroids-for-copd-exacerbation-management
#2
Jordan A Pearce, Dane L Shiltz, Qian Ding
BACKGROUND: Only 1 small, single-center study has evaluated the combination of systemic plus inhaled corticosteroid (ICS) routes for chronic obstructive pulmonary disease (COPD) exacerbation management. This study aims to further improve the existing quantity and quality of evidence regarding the utility for combination therapy in the management of COPD exacerbation. OBJECTIVES: To evaluate length of hospital stay, readmission rate, incidence of infection, and mortality in hospitalized patients who experience a COPD exacerbation and receive systemic corticosteroid therapy with or without concurrent ICS...
May 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29779416/long-term-triple-therapy-de-escalation-to-indacaterol-glycopyrronium-in-copd-patients-sunset-a-randomized-double-blind-triple-dummy-clinical-trial
#3
Kenneth R Chapman, John R Hurst, Stefan-Marian Frent, Michael Larbig, Robert Fogel, Tadhg Guerin, Donald Banerji, Francesco Patalano, Pankaj Goyal, Pascal Pfister, Konstantinos Kostikas, Jadwiga A Wedzicha
RATIONALE: There are no studies on ICS withdrawal in patients on long-term triple therapy in the absence of frequent exacerbations. OBJECTIVE: To evaluate the efficacy and safety of the direct de-escalation from long-term triple therapy to indacaterol/glycopyrronium in non-frequently exacerbating COPD patients. METHODS: This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/glycopyrronium (110/50μg once daily) or continuation of triple therapy (tiotropium 18μg once daily plus combination of salmeterol/fluticasone propionate [50/500μg] twice daily) in non-frequently exacerbating patients with moderate-to-severe COPD...
May 20, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29750142/single-inhaler-triple-therapy-in-symptomatic-copd-patients-fulfil-subgroup-analyses
#4
David M G Halpin, Ruby Birk, Noushin Brealey, Gerard J Criner, Mark T Dransfield, Emma Hilton, David A Lomas, Chang-Qing Zhu, David A Lipson
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2 -agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear. FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29741897/novel-pyrrolidine-derivatives-of-budesonide-as-long-acting-inhaled-corticosteroids-for-the-treatment-of-pulmonary-inflammatory-diseases
#5
Eleonora Ghidini, Gessica Marchini, Anna Maria Capelli, Chiara Carnini, Valentina Cenacchi, Alessandro Fioni, Fabrizio Facchinetti, Fabio Rancati
Inhaled corticosteroids (ICS) represent the first line therapy for the treatment of asthma and are also extensively utilized in chronic obstructive pulmonary disease. Our goal was to develop a new ICS with a basic group which can allow solid state feature modulation, achieving at the same time high local antiinflammatory effect and low systemic exposure. Through a rational drug design approach a new series of a pyrrolidine derivatives of budesonide was identified. Within the series, several compounds showed nanomolar binding affinity (Ki) with GR that mostly correlated with the effect in inducing GR nuclear translocation in CHO cells and anti-inflammatory effects in macrophagic cell lines...
May 9, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29724175/risk-and-impact-of-herpes-zoster-among-copd-patients-a-population-based-study-2009-2014
#6
Cintia Muñoz-Quiles, Mónica López-Lacort, Javier Díez-Domingo
BACKGROUND: The objective of this study was to assess the incidence of Herpes Zoster (HZ) among patients with chronic obstructive pulmonary disease (COPD) and the impact of HZ on the underlying COPD. METHODS: A retrospective cohort of all subjects older than 49 years was followed up between 2009 and 2014 using population and health databases of Valencia Region (Spain). HZ and COPD were identified using ICD-9 codes, differentiating COPD patients with inhaled corticosteroids prescriptions (COPD-ICS)...
May 3, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29719507/breathomics-for-assessing-the-effects-of-treatment-and-withdrawal-with-inhaled-beclomethasone-formoterol-in-patients-with-copd
#7
Paolo Montuschi, Giuseppe Santini, Nadia Mores, Alessia Vignoli, Francesco Macagno, Rugia Shoreh, Leonardo Tenori, Gina Zini, Leonello Fuso, Chiara Mondino, Corrado Di Natale, Arnaldo D'Amico, Claudio Luchinat, Peter J Barnes, Tim Higenbottam
Background: Prospective pharmacological studies on breathomics profiles in COPD patients have not been previously reported. We assessed the effects of treatment and withdrawal of an extrafine inhaled corticosteroid (ICS)-long-acting β2 -agonist (LABA) fixed dose combination (FDC) using a multidimensional classification model including breathomics. Methods: A pilot, proof-of-concept, pharmacological study was undertaken in 14 COPD patients on maintenance treatment with inhaled fluticasone propionate/salmeterol (500/50 μg b...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29713156/indacaterol-glycopyrronium-reduces-the-risk-of-clinically-important-deterioration-after-direct-switch-from-baseline-therapies-in-patients-with-moderate-copd-a-post-hoc-analysis-of-the-crystal-study
#8
Timm Greulich, Konstantinos Kostikas, Mina Gaga, Maryam Aalamian-Mattheis, Nadine S Lossi, Francesco Patalano, Xavier Nunez, Veronica A Pagano, Robert Fogel, Claus F Vogelmeier, Andreas Clemens
Purpose: COPD is a progressive disease characterized by exacerbations and a decline in health status and lung function. Clinically important deterioration (CID) is a composite endpoint used to evaluate treatment efficacy. This analysis evaluated the impact of a direct switch to once-daily indacaterol/glycopyrronium 110/50 µg (IND/GLY) from previous monotherapy with a long-acting β2 -agonist (LABA) or long-acting muscarinic antagonist (LAMA) or with an LABA and an inhaled corticosteroid (LABA + ICS) on reducing CID...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29696728/predictive-value-of-eosinophils-and-neutrophils-on-clinical-effects-of-ics-in-copd
#9
Floor J Hartjes, Judith M Vonk, Alen Faiz, Pieter S Hiemstra, Thérèse S Lapperre, Huib A M Kerstjens, Dirkje S Postma, Maarten van den Berge
BACKGROUND AND OBJECTIVE: Inflammation is present to a variable degree and composition in patients with COPD. This study investigates associations between both eosinophils and neutrophils in blood, sputum, airway wall biopsies and bronchoalveolar lavage (BAL) and their potential use as biomarkers for clinical response to inhaled corticosteroids (ICS). METHODS: In total, 114 steroid-naïve COPD patients of the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study using ICS or placebo during 30-month follow-up were included...
April 26, 2018: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/29679596/observational-studies-of-inhaled-corticosteroid-effectiveness-in-copd-lessons-learned
#10
Samy Suissa, Pierre Ernst
BACKGROUND: Randomized controlled trials at times investigate findings suggested by observational studies. For example, the TORCH trial, which did not show a mortality reduction with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), was motivated by some observational studies that suggested considerable reductions in mortality with these drugs. Reasons for these discrepancies are unclear. METHODS: We searched the literature to identify all observational studies, including cohort and case-control studies, investigating the effectiveness of ICS on major outcomes in COPD patients, including death and hospitalization for COPD...
April 18, 2018: Chest
https://www.readbyqxmd.com/read/29670674/tiotropium-for-the-treatment-of-asthma-patient-selection-and-perspectives
#11
REVIEW
V Madhu Chari, Robert Andrew McIvor
Asthma is a chronic disease of airway inflammation with a large global burden. Despite established, guideline-based stepwise therapy, a significant proportion of patients remain symptomatic and poorly controlled. As such, there is a need for additional safe, effective, convenient, and cost-effective therapies that can be broadly applied across a range of asthma phenotypes. Tiotropium is a long-acting muscarinic antagonist (LAMA) that leads to bronchodilation by blocking endogenous acetylcholine receptors in the airways...
2018: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
https://www.readbyqxmd.com/read/29650761/once-daily-triple-therapy-inhaler-for-copd
#12
(no author information available yet)
▼Trelegy Ellipta (GSK) is a dry powder inhaler containing fluticasone furoate (inhaled corticosteroid [ICS]), vilanterol trifenatate (long-acting beta2 agonist [LABA]) and umeclidinium bromide (long-acting muscarinic antagonist [LAMA]).1 It is licensed for once-daily use as maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. Here, we consider the evidence for this combination product and discuss how it fits with current management strategies...
April 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29642882/assessing-the-healthcare-resource-use-associated-with-inappropriate-prescribing-of-inhaled-corticosteroids-for-people-with-chronic-obstructive-pulmonary-disease-copd-in-gold-groups-a-or-b-an-observational-study-using-the-clinical-practice-research-datalink
#13
James D Chalmers, Chris Poole, Samantha Webster, Abigail Tebboth, Scott Dickinson, Alicia Gayle
BACKGROUND: Recent recommendations from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) position inhaled corticosteroids (ICS) for use in chronic obstructive pulmonary disease (COPD) patients experiencing exacerbations (≥ 2 or ≥ 1 requiring hospitalisation); i.e. GOLD groups C and D. However, it is known that ICS is frequently prescribed for patients with less severe COPD. Potential drivers of inappropriate ICS use may be historical clinical guidance or a belief among physicians that intervening early with ICS would improve outcomes and reduce resource use...
April 11, 2018: Respiratory Research
https://www.readbyqxmd.com/read/29629401/pattern-and-adherence-to-maintenance-medication-use-in-medicare-beneficiaries-with-chronic-obstructive-pulmonary-disease-2008-2013
#14
Shawn P E Nishi, Matthew Maslonka, Wei Zhang, Yong-Fang Kuo, Gulshan Sharma
Background: Maintenance medications provide symptomatic relief, improve lung function and reduce the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Despite their proven benefits, limited information exists on maintenance medication use and adherence among users. Objective: We examined the patterns and factors associated with the receipt of and adherence to maintenance medication in individuals with COPD. Methods: A retrospective cross-sectional study of 5% of Medicare beneficiaries enrolled in Parts A, B and D with COPD who received maintenance medication from 2008 to 2013 was conducted...
January 24, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://www.readbyqxmd.com/read/29605621/is-ics-lama-an-alternative-option-to-treat-patients-with-copd
#15
COMMENT
Paola Rogliani, Luigino Calzetta, Mario Cazzola
No abstract text is available yet for this article.
May 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29572448/improvement-in-the-management-of-chronic-obstructive-pulmonary-disease-following-a-clinical-educational-program-results-from-a-prospective-cohort-study-in-the-sicilian-general-practice-setting
#16
Rosarita Ferrara, Valentina Ientile, Carlo Piccinni, Alessandro Pasqua, Serena Pecchioli, Andrea Fontana, Umberto Alecci, Riccardo Scoglio, Francesco Magliozzo, Sebastiano Emanuele Torrisi, Carlo Vancheri, Patrizio Vitulo, Giovanna Fantaci, Carmen Ferrajolo, Mario Cazzola, Claudio Cricelli, Achille Patrizio Caputi, Gianluca Trifirò
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disorder of the lungs associated with progressive disability. Although general practitioners (GPs) should play an important role in the COPD management, critical issues have been documented in the primary care setting. The aim of this study was to evaluate the effectiveness of an educational program for the improvement of the COPD management in a Sicilian general practice setting. The effectiveness of the program, was evaluated by comparing 15 quality-of-care indicators developed from data extracted by 33 GPs, at baseline vs...
March 23, 2018: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/29551894/factors-influencing-treatment-escalation-from-long-acting-muscarinic-antagonist-monotherapy-to-triple-therapy-in-patients-with-copd-a-retrospective-thin-database-analysis
#17
John R Hurst, Maria Dilleen, Kevin Morris, Siân Hills, Birol Emir, Rupert Jones
Purpose: Inappropriate use of an inhaled corticosteroid (ICS) for COPD has clinical and economic disadvantages. This retrospective analysis of The UK Health Improvement Network (THIN) database identified factors influencing treatment escalation (step-up) from a long-acting muscarinic antagonist (LAMA) to triple therapy (LAMA + long-acting β-agonist-ICS). Secondary objectives included time to step up from first LAMA prescription, Global Initiative for Chronic Obstructive Lung Disease (GOLD) grouping (2011/2013, 2017), and Medical Research Council (MRC) grade prior to treatment escalation...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29549687/role-of-inhaled-corticosteroids-in-the-exacerbation-rate-of-moderate-chronic-obstructive-pulmonary-disease
#18
Maida Rakanović Todić, Sanita Maleškić, Lejla Burnazović Ristić, Aida Kulo Ćesić, Jasna Kusturica, Besim Prnjavorac
Aim To analyse frequency of chronic obstructive pulmonary disease (COPD) exacerbation in patients on therapy with inhaled corticosteroids (ICS) and relevant factors that influence the rate of COPD exacerbations in a subgroup of moderate illness, like FEV1, comorbidities and other concomitant therapy. Methods The study included patients with moderate COPD with at least 10 pack-years history of smoking and accompanying cardiovascular comorbidity. Demographic data, frequency of exacerbations and information about proscribed treatments - ICS alone or in combination with long acting beta agonist (LABA), were collected from medical records for the previous 12 months from the index date...
February 1, 2018: Medicinski Glasnik
https://www.readbyqxmd.com/read/29537340/single-inhaler-triple-therapy-utilizing-the-once-daily-combination-of-fluticasone-furoate-umeclidinium-and-vilanterol-in-the-management-of-copd-the-current-evidence-base-and-future-prospects
#19
Mario Malerba, Matteo Nardin, Giuseppe Santini, Nadia Mores, Alessandro Radaeli, Paolo Montuschi
Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2 -adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' daily symptoms and reduce decline of pulmonary function and acute exacerbation rate. Treatment with all three inhaled drug classes is reserved for selected, more severe, patients with COPD when symptoms are not sufficiently controlled by dual LABA/LAMA therapy and exacerbations are frequent...
January 2018: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/29524387/considerations-for-the-correct-diagnosis-of-copd-and-its-management-with-bronchodilators
#20
Antonio Anzueto, Marc Miravitlles
COPD is often misdiagnosed and inappropriately treated in many patients. COPD is a distinct disease from adult-onset asthma; however, some patients with COPD may present with several forms of airway disease described as asthma-COPD overlap (ACO). Bronchodilators and inhaled corticosteroids (ICS) both have a place in standard maintenance treatment of COPD and asthma; however, recommendations for use differ widely. In patients with COPD, long-acting bronchodilators are effective initial monotherapy treatment, whereas ICS monotherapy is recommended as initial treatment in patients with asthma...
March 8, 2018: Chest
keyword
keyword
119712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"